Meeting
2023 ASCO Annual Meeting
Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors.
Authors
Jesús Fuentes Antrás
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
Jesús Fuentes Antrás , Samah El Ghamrasni , Jinfeng Zou , Aaron Dou , Mitchell J. Elliott , Lisa Avery , Scott Victor Bratman , David W. Cescon , Philippe L. Bedard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1075)
DOI
10.1200/JCO.2023.41.16_suppl.1075
Abstract #
1075
Poster Bd #
296
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Molecular alterations associated with rapid progression following CDK4/6 inhibitors (CDKi) in metastatic hormone receptor–positive breast cancer (mHRBC).
First Author: Malinda T West
Poster
2020 ASCO Virtual Scientific Program
Detection of actionable gene mutations in breast cancer by amplicon-based next-generation sequencing liquid biopsy.
First Author: Jing Shan Lim
Poster
2022 ASCO Annual Meeting
Defining resistance mechanisms to CDK4/6 inhibition in hormone receptor-positive HER2-negative metastatic breast cancer (MBC) through a machine learning approach applied to circulating tumor DNA (ctDNA).
First Author: Lorenzo Gerratana
Poster
2021 ASCO Annual Meeting
The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
First Author: Kelvin K H Bao